Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 170

1.

Iloperidone, asenapine, and lurasidone: a brief overview of 3 new second-generation antipsychotics.

Citrome L.

Postgrad Med. 2011 Mar;123(2):153-62. doi: 10.3810/pgm.2011.03.2273. Review.

PMID:
21474903
2.

Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis.

De Hert M, Yu W, Detraux J, Sweers K, van Winkel R, Correll CU.

CNS Drugs. 2012 Sep 1;26(9):733-59. doi: 10.2165/11634500-000000000-00000. Review.

PMID:
22900950
3.

Iloperidone, asenapine and lurasidone: a primer on their current status.

Tarazi FI, Stahl SM.

Expert Opin Pharmacother. 2012 Sep;13(13):1911-22. doi: 10.1517/14656566.2012.712114. Review.

PMID:
22849428
4.

Asenapine, iloperidone and lurasidone: critical appraisal of the most recently approved pharmacotherapies for schizophrenia in adults.

Bobo WV.

Expert Rev Clin Pharmacol. 2013 Jan;6(1):61-91. doi: 10.1586/ecp.12.70. Review.

PMID:
23272794
5.

Update on newer antipsychotic drugs.

Howland RH.

J Psychosoc Nurs Ment Health Serv. 2011 Apr;49(4):13-5. doi: 10.3928/02793695-20110311-99.

PMID:
21446639
6.

Asenapine, blonanserin, iloperidone, lurasidone, and sertindole: distinctive clinical characteristics of 5 novel atypical antipsychotics.

Wang SM, Han C, Lee SJ, Patkar AA, Masand PS, Pae CU.

Clin Neuropharmacol. 2013 Nov-Dec;36(6):223-38. doi: 10.1097/WNF.0b013e3182aa38c4. Review.

PMID:
24201235
7.

Newer antipsychotics and upcoming molecules for schizophrenia.

George M, Amrutheshwar R, Rajkumar RP, Kattimani S, Dkhar SA.

Eur J Clin Pharmacol. 2013 Aug;69(8):1497-509. doi: 10.1007/s00228-013-1498-4. Review.

PMID:
23545936
8.
9.

Four-week, double-blind, placebo- and ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophrenia.

Cutler AJ, Kalali AH, Weiden PJ, Hamilton J, Wolfgang CD.

J Clin Psychopharmacol. 2008 Apr;28(2 Suppl 1):S20-8. doi: 10.1097/JCP.0b013e318169d4ce.

PMID:
18334909
10.

Effectiveness of lurasidone in patients with schizophrenia or schizoaffective disorder switched from other antipsychotics: a randomized, 6-week, open-label study.

McEvoy JP, Citrome L, Hernandez D, Cucchiaro J, Hsu J, Pikalov A, Loebel A.

J Clin Psychiatry. 2013 Feb;74(2):170-9. doi: 10.4088/JCP.12m07992.

11.

Lurasidone for schizophrenia: a review of the efficacy and safety profile for this newly approved second-generation antipsychotic.

Citrome L.

Int J Clin Pract. 2011 Feb;65(2):189-210. doi: 10.1111/j.1742-1241.2010.02587.x. Review.

PMID:
21129135
12.
13.

[Short-term efficacy and safety of lurasidone in the treatment of schizophrenia].

Samalin L, Ben Gharbia M, Garnier M, Llorca PM.

Encephale. 2014 Dec;40(6):507-17. Review. French.

PMID:
25453735
14.

Lurasidone for schizophrenia: a brief review of a new second-generation antipsychotic.

Citrome L.

Clin Schizophr Relat Psychoses. 2011 Jan;4(4):251-7. doi: 10.3371/CSRP.4.4.5. Review.

PMID:
21177242
15.
16.
17.

Lurasidone : in the treatment of schizophrenia.

Sanford M.

CNS Drugs. 2013 Jan;27(1):67-80. doi: 10.1007/s40263-012-0026-x. Review.

PMID:
23264146
18.

Lurasidone: a clinical overview.

Kane JM.

J Clin Psychiatry. 2011;72 Suppl 1:24-8. doi: 10.4088/JCP.10075su1.05. Review.

19.

Iloperidone: a clinical overview.

Citrome L.

J Clin Psychiatry. 2011;72 Suppl 1:19-23. doi: 10.4088/JCP.10075su1.04. Review.

20.

Safety profile of iloperidone: a pooled analysis of 6-week acute-phase pivotal trials.

Weiden PJ, Cutler AJ, Polymeropoulos MH, Wolfgang CD.

J Clin Psychopharmacol. 2008 Apr;28(2 Suppl 1):S12-9. doi: 10.1097/JCP.0b013e3181694f5a.

PMID:
18334908

Supplemental Content

Support Center